Skin Analytics, a London, UK-based medtech company, raised £15m in Series B funding.
The round was led by Intrepid Partners.
The company intends to use the funds to hire new people, launch dermatology products, as well as expand internationally to new markets including Europe and Australia, and prepare for US market launch.
Led by Neil Daly, founder and CEO, Skin Analytics is advancing DERM (Deep Ensemble for the Recognition of Malignancy), a Class IIa UKCA marked and Class III CE marked AI as a Medical Device (AIaMD) that assesses dermoscopic images of skin lesions for skin cancer.
Its pathways enable NHS organisations to discharge benign lesions earlier in the pathway and therefore tackle backlog, free up out-patient delays and reserve limited dermatology capacity to prioritise patients with skin cancer by focusing on providing potentially life-saving treatment.
FinSMEs
16/04/2025